Pharmacological Management of Post-Traumatic Stress Disorder Symptoms

Post-traumatic stress disorder (PTSD) is characterised by persistent re-experiencing of trauma, avoidance behaviours, negative alterations in cognition and mood, and hyperarousal. Pharmacological interventions aim to alleviate these core symptoms, improve sleep quality and reduce the burden of flashbacks and nightmares. First-line treatments typically involve selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), which modulate monoaminergic pathways to stabilise mood and anxiety. Many patients, however, exhibit partial response or intolerance to these agents, prompting interest in adjunctive strategies. Alpha-1-adrenergic antagonists such as prazosin and clonidine have demonstrated particular efficacy in targeting trauma-related nightmares and hyperarousal by dampening noradrenergic signalling during sleep. Emerging treatments include synthetic cannabinoids and histamine antagonists, which may act via distinct neural circuits involved in memory consolidation and arousal. Novel agents, notably NMDA receptor modulators and rapid-acting antidepressants such as ketamine, are under investigation for their capacity to promote synaptic plasticity and address treatment-resistant presentations. The overarching trend is towards combination regimens and personalised medicine approaches that integrate pharmacotherapy with trauma-focused psychotherapies, guided by biomarkers and sleep architecture assessments. Ongoing research seeks to refine dosing schedules, reduce adverse effects and extend therapeutic benefit across diverse populations and healthcare settings.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Management of Post-Traumatic Stress Disorder Symptoms publication trend

The graph below shows the total number of articles in pharmacological management of post-traumatic stress disorder symptoms across all publications each year (not limited to Nature Index journals).

Technical terms

α1-adrenergic antagonist: A drug that blocks alpha-1 receptors in the nervous system, reducing noradrenaline-mediated arousal and nightmares.

Rapid eye movement (REM) sleep: A sleep stage characterised by vivid dreaming, during which PTSD-related intrusions and nightmares often occur.

Selective serotonin reuptake inhibitors (SSRIs): Medications that increase serotonin levels in the brain by inhibiting its reuptake, commonly used to treat PTSD and depression.

Effect size: A statistical measure that quantifies the magnitude of a treatment’s impact, aiding comparison across clinical trials.

References

1. The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials. International Journal of Environmental Research and Public Health (2022).
2. Case series: Continued remission of PTSD symptoms after discontinuation of prazosin. Frontiers in Psychiatry (2023).
3. Clonidine Use for the Treatment of Nightmares in Posttraumatic Stress Disorder. Case Reports in Psychiatry (2022).